Repligen Corp. 10-Q Summary: Period Ended December 31, 1999
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Repligen Corporation for the three and nine months ended December 31, 1999. Repligen is a biotechnology company developing drugs for autism, organ transplantation, and cancer, while also manufacturing products for therapeutic antibody production. The company operates as a single segment with significant revenue concentration in the United States (75% for the nine-month period).
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1999 | Nine Months Ended Dec 31, 1999 | Nine Months Ended Dec 31, 1998 |
|---|---|---|---|
| Total Revenues | $864,318 | $2,534,509 | $1,943,734 |
| Net Loss | $(1,734,644) | $(2,962,000) | $(867,728) |
| Net Loss Per Share (Basic/Diluted) | $(0.08) | $(0.14) | $(0.05) |
| Cash and Cash Equivalents | $9,295,868 (End of Period) | Increased $6.0M from prior fiscal year end | |
| Working Capital | $10,031,400 | Increased from $3.86M at March 31, 1999 | |
| Net Cash Used in Operating Activities | $(2,660,084) for nine months ended Dec 31, 1999 | ||
| Net Cash Provided by Financing | $8,915,368 for nine months ended Dec 31, 1999 |
Revenue Composition (Nine Months 1999): Product sales ($1.37M), Research & Development ($771K), Investment Income ($334K), Other ($60K).
Expense Composition (Nine Months 1999): R&D Expenses ($3.09M), SG&A ($1.64M), Cost of Products Sold ($775K).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 47% quarter-over-quarter and 30% year-to-date. Product revenues surged 124% (Q3) and 103% (YTD) driven by shipments to Amersham Pharmacia Biotech. Investment income rose 159% (Q3) due to higher cash balances from a private placement.
- Expense Surge: Total expenses increased 184% (Q3) and 96% (YTD). R&D expenses jumped 342% (Q3) primarily due to a $1.0 million upfront payment for a licensing agreement with ChiRhoClin Inc. and increased drug development costs.
- Liquidity Improvement: Cash balances grew from $3.25M to $9.30M, fueled by $8.9M in net proceeds from a private placement of common stock closed in June 1999.
- Customer Concentration: One customer accounted for approximately 30% of revenues in the quarter ended December 31, 1999.
Guidance, Outlook, and Risks
- Outlook: Management anticipates increased operating costs in fiscal 2000 due to expanded proprietary product development. The company believes current funding is sufficient for the next 24 months.
- Strategic Developments:
- Secretin: Acquired exclusive rights for autism treatment; licensed diagnostic products from ChiRhoClin (subject to future milestone payments upon FDA approval).
- CTLA4-Ig: Phase 1 trial results showed prevention of Graft Versus Host Disease in 8 of 11 patients. Phase 2 trial with National Cancer Institute initiated.
- Protein A: Entered a 10-year supply agreement with Amersham Pharmacia Biotech.
- Risks and Contingencies:
- Legal Proceedings: A lawsuit against Bristol-Myers Squibb regarding inventorship of CTLA4-Ig patents was dismissed without prejudice in July 1999 due to lack of standing. Repligen intends to pursue correction of inventorship; failure to do so may restrict commercialization rights.
- Financing: Future funding may be required, but the volatile biotech market could make securing capital on favorable terms difficult.
- Year 2000: No significant disruptions reported, though risks remain regarding third-party suppliers.
Investor Verification Checklist
- Verify the status of the $1.0 million licensing payment to ChiRhoClin and the timeline for potential future milestone payments contingent on FDA approval.
- Confirm the progress of the Phase 2 clinical trial for CTLA4-Ig with the National Cancer Institute.
- Review the details of the dismissed lawsuit against Bristol-Myers Squibb and the company's strategy to regain patent rights for CTLA4-Ig.
- Assess the sustainability of the 124% increase in product revenue, specifically the reliance on the Amersham Pharmacia Biotech contract.
- Monitor cash burn rate given the significant increase in R&D expenses and the company's reliance on future financing if the 24-month runway is exceeded.